Enclosed herewith Outcome of the Board Meeting held on February 10, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.5 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Daikaffil Chemicals India Ltd's Board approved its unaudited financial results for Q3 FY26 and the nine months ended December 31, 2025, with an unmodified opinion from statutory auditors N V C & Associates LLP (standalone and consolidated). For Q3 FY26 (standalone), revenue from operations was ₹146.81 Lacs (vs ₹349.87 Lacs in Q3 FY25), while for the nine-month period revenue surged to ₹1,138.10 Lacs from ₹349.87 Lacs in the prior year — roughly a 3x jump. The company continued to post losses, with a Q3 FY26 net loss of ₹33.72 Lacs and a nine-month net loss of ₹124.97 Lacs (vs ₹124.08 Lacs in 9M FY25). This is the first set of consolidated results filed by the company, following the incorporation of wholly-owned subsidiary Mikusu Global Industries Limited in August 2025. The subsidiary contributed negligible revenue but a small loss of ₹3.78 Lacs. Diluted EPS for 9M FY26 stood at ₹(2.08), roughly flat with the prior year.
Mixed picture for shareholders — a sharp jump in nine-month revenue points to scaling-up, but persistent quarterly losses and a sharp sequential and YoY revenue dip in Q3 FY26 raise concerns about demand consistency. The stock remains a small-cap, loss-making name where profitability, not just topline, will be the key driver of any re-rating.